IGF-1 LR3
Long R3 Insulin-like Growth Factor-1
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.
Complete Research Database
Alzheimer's Plaque Study
View StudyIntranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex
PRIMARY RESULTS
Reduced filamentous amyloid plaques but no cognitive function improvement in 5XFAD mouse model
KEY FINDINGS
- •Significant amyloid plaque remodeling in cerebral cortex
- •No preservation of cognitive function
- •Intranasal delivery showed brain tissue penetration
Fetal Growth Study
View StudyReduced glucose-stimulated insulin secretion following IGF-1 infusion in fetal sheep
PRIMARY RESULTS
Decreased plasma insulin and impaired glucose-stimulated insulin secretion despite growth factor treatment
KEY FINDINGS
- •Reduced amino acid concentrations indicating increased utilization
- •Impaired pancreatic beta-cell function
- •No significant improvement in fetal growth restriction
Vascular Development Study
View StudyEffects of IGF-I and LR3IGF-I on regional blood flow in normal rats
PRIMARY RESULTS
Significant increases in regional blood flow and enhanced angiogenesis in target tissues
KEY FINDINGS
- •Enhanced regional blood flow by 25-35%
- •Improved vascular development and angiogenesis
- •Tissue-specific growth promotion effects
Medical Disclaimer
IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.